A Phase 2 interventional study of pemetrexed in Neoplasms, Neoplasms by Site and Urogenital Neoplasms, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2009-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Endometrial Neoplasms by Eli Lilly and Company — 4 open to participants now, 8 under way, none of them phase 3. Endometrial Neoplasms · Eli Lilly and Company.
Among the 11 studies in Endometrial Neoplasms by Eli Lilly and Company, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2006, is one of 2 in phase 2, and was the 3rd registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →4 of the 11 studies in Endometrial Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, France and 6 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, France, Japan and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 400 across the 10 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Endometrial Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04956640Eli Lilly and CompanyStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Endometrial Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
This study's enrollment of 27 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Endometrial Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed
900 mg/m2, intravenous (IV), every 21 days, until disease progression
Also known as: LY231514, Alimta
Tumor Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (up to 24 months)
Number of Participants With Adverse Events by Grade (Measures of Toxicity)
Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.
Time frame: every 21-day cycle (up to 24 months)
| Milestone | Pemetrexed |
|---|---|
| Started | 27 |
| Completed | 26 |
| Not completed | 1 |
| Withdrew: Ineligible (prior radiation) | 1 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.
| participants | Pemetrexed |
|---|---|
| Completed Response | 0 |
| Partial Response | 1 |
| Stable Disease | 12 |
| Progressive Disease | 11 |
| Inevaluable | 2 |
Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.
| participants | Pemetrexed |
|---|---|
| Leukopenia - Grade 1 | 3 |
| Leukopenia - Grade 2 | 4 |
| Leukopenia - Grade 3 | 8 |
| Leukopenia - Grade 4 | 2 |
| Thrombocytopenia - Grade 1 | 7 |
| Thrombocytopenia - Grade 2 | 1 |
| Thrombocytopenia - Grade 3 | 4 |
| Thrombocytopenia - Grade 4 | 0 |
| Neutropenia - Grade 1 | 2 |
| Neutropenia - Grade 2 | 3 |
| Neutropenia - Grade 3 | 9 |
| Neutropenia - Grade 4 | 3 |
| Anemia - Grade 1 | 9 |
| Anemia - Grade 2 | 11 |
| Anemia - Grade 3 | 5 |
| Anemia - Grade 4 | 0 |
| Coagulation - Grade 1 | 0 |
| Coagulation - Grade 2 | 0 |
| Coagulation - Grade 3 | 1 |
| Coagulation - Grade 4 | 0 |
| Nausea/vomiting - Grade 1 | 5 |
| Nausea/vomiting - Grade 2 | 2 |
| Nausea/vomiting - Grade 3 | 2 |
| Nausea/vomiting - Grade 4 | 0 |
| Gastrointestinal - Grade 1 | 6 |
| Gastrointestinal - Grade 2 | 6 |
| Gastrointestinal - Grade 3 | 3 |
| Gastrointestinal - Grade 4 | 0 |
| Alopecia - Grade 1 | 1 |
| Alopecia - Grade 2 | 0 |
| Dermatologic - Grade 1 | 4 |
| Dermatologic - Grade 2 | 2 |
| Dermatologic - Grade 3 | 1 |
| Dermatologic - Grade 4 | 0 |
| Alkaline phosphatase - Grade 1 | 4 |
| Alkaline phosphatase - Grade 2 | 0 |
| Alkaline phosphatase - Grade 3 | 0 |
| Alkaline phosphatase - Grade 4 | 0 |
| Serum glutamic-oxaloacetic transaminase - Grade 1 | 3 |
| Serum glutamic-oxaloacetic transaminase - Grade 2 | 0 |
| Serum glutamic-oxaloacetic transaminase - Grade 3 | 0 |
| Serum glutamic-oxaloacetic transaminase - Grade 4 | 0 |
| Neurologic - Grade 1 | 6 |
| Neurologic - Grade 2 | 3 |
| Neurologic - Grade 3 | 0 |
| Neurologic - Grade 4 | 1 |
| Infection - Grade 1 | 0 |
| Infection - Grade 2 | 4 |
| Infection - Grade 3 | 2 |
| Infection - Grade 4 | 0 |
| Pulmonary - Grade 1 | 2 |
| Pulmonary - Grade 2 | 0 |
| Pulmonary - Grade 3 | 0 |
| Pulmonary - Grade 4 | 0 |
| Metabolic - Grade 1 | 7 |
| Metabolic - Grade 2 | 1 |
| Metabolic - Grade 3 | 0 |
| Metabolic - Grade 4 | 0 |
| Lymphatics - Grade 1 | 3 |
| Lymphatics - Grade 2 | 0 |
| Lymphatics - Grade 3 | 1 |
| Lymphatics - Grade 4 | 0 |
| Pain - Grade 1 | 3 |
| Pain - Grade 2 | 2 |
| Pain - Grade 3 | 3 |
| Pain - Grade 4 | 0 |
| Constitutional - Grade 1 | 4 |
| Constitutional - Grade 2 | 8 |
| Constitutional - Grade 3 | 5 |
| Constitutional - Grade 4 | 0 |
| Renal - Grade 1 | 1 |
| Renal - Grade 2 | 0 |
| Renal - Grade 3 | 0 |
| Renal - Grade 4 | 0 |
| Musculoskeletal - Grade 1 | 1 |
| Musculoskeletal - Grade 2 | 1 |
| Musculoskeletal - Grade 3 | 0 |
| Musculoskeletal - Grade 4 | 0 |
| Ocular - Grade 1 | 2 |
| Ocular - Grade 2 | 1 |
| Ocular - Grade 3 | 0 |
| Ocular - Grade 4 | 0 |
| Cardiovascular - Grade 1 | 1 |
| Cardiovascular - Grade 2 | 1 |
| Cardiovascular - Grade 3 | 0 |
| Cardiovascular - Grade 4 | 0 |
| Vascular - Grade 1 | 0 |
| Vascular - Grade 2 | 0 |
| Vascular - Grade 3 | 1 |
| Vascular - Grade 4 | 0 |
| Endocrine - Grade 1 | 0 |
| Endocrine - Grade 2 | 1 |
| Endocrine - Grade 3 | 0 |
| Endocrine - Grade 4 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 6/26 (23.1%) | 26/26 (100%) |
| Event | Pemetrexed |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/26 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/26 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/26 |
| Gastrointestinal fistulaGastrointestinal disorders | 1/26 |
| DehydrationMetabolism and nutrition disorders | 1/26 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/26 |
| AtaxiaNervous system disorders | 1/26 |
| SyncopeNervous system disorders | 1/26 |
| Renal failure acuteRenal and urinary disorders | 1/26 |
| Event | Pemetrexed |
|---|---|
| AnemiaBlood and lymphatic system disorders | 25/26 |
| LeukopeniaBlood and lymphatic system disorders | 17/26 |
| NeutropeniaBlood and lymphatic system disorders | 17/26 |
| ConstitutionalGeneral disorders | 17/26 |
| GastrointestinalGastrointestinal disorders | 15/26 |
| ThrombocytopeniaBlood and lymphatic system disorders | 12/26 |
| NeurologicNervous system disorders | 10/26 |
| Nausea/vomitingGastrointestinal disorders | 9/26 |
| PainGeneral disorders | 8/26 |
| MetabolicMetabolism and nutrition disorders | 8/26 |
| Age, Customized(participants) | Pemetrexed |
|---|---|
| 40-49 years | 3 |
| 50-59 years | 6 |
| 60-69 years | 10 |
| >69 years | 7 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 26 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Pemetrexed |
|---|---|
| White | 22 |
| Black | 3 |
| Asian | 1 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| United States | 26 |
| Grade (Histology)(participants) | Pemetrexed |
|---|---|
| G1 - Well-Differentiated | 5 |
| G2 - Moderately Differentiated | 8 |
| G3 - Poorly Differentiated | 13 |
| Gynecologic Oncology Group (GOG) Performance Status(participants) | Pemetrexed |
|---|---|
| 0 - Fully active | 14 |
| 1 - Ambulatory, Restricted Strenuous Activity | 12 |
| Prior Treatment(participants) | Pemetrexed |
|---|---|
| Prior Chemotherapy | 26 |
| No Prior Chemotherapy | 0 |
| Prior Radiotherapy | 12 |
| No Prior Radiotherapy | 14 |
The record gives a start of Sep 2006, a primary completion of Oct 2007 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed